Holen Sie sich die Stockscreener-App
0.4318
1.53%
-0.0067
Handel nachbörslich:
.43
-0.0018
-0.42%
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines - Traders Union
Outlook Therapeutics (OTLK) Advances Towards FDA Approval for ONS-5010 - GuruFocus
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval - TipRanks
Outlook Therapeutics Offers Update After FDA Meeting About ONS-5010/LYTENAVA - marketscreener.com
Outlook Therapeutics provides update following Type A meeting with FDA - marketscreener.com
Outlook Therapeutics Provides Update Following Type A Meeting With FDA - TradingView
Outlook Therapeutics (Nasdaq: OTLK) details FDA Type A meeting on ONS-5010 - Stock Titan
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com India
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) - Yahoo! Finance Canada
Can Outlook Therapeutics Inc reach all time highs this yearJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Risk On: Will Outlook Therapeutics Inc benefit from AI trendsJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
OTLK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buyback Watch: Is Old Point Financial Corporation a good ESG investment2025 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
OTLKW News Today: Stay Updated with the Latest Outlook Therapeutics, Inc.Se News in Real Time - Meyka
Aug Macro: Will Outlook Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Key facts: Outlook Therapeutics Faces Nasdaq Compliance Deadline; Signs Deal with Mediconsult AG - TradingView
Outlook Therapeutics Signs Exclusive Distribution Deal With Mediconsult for Lytenava - marketscreener.com
Outlook Therapeutics (OTLK) Secures Swiss Distribution Deal for Lytenava - GuruFocus
Outlook Therapeutics, Inc. accelerates its European market expansion plan through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Can Outlook Break The Cycle With Fresh FDA Meeting On Ophthalmic Bevacizumab? - Citeline News & Insights
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - The Manila Times
Outlook Therapeutics, Inc. accelerates its European market expansion plans through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Outlook Therapeutics Reports Q1 Fiscal Year 2026 Financial Results - VisionMonday.com
Outlook Therapeutics (OTLK) Maintains Neutral Rating According t - GuruFocus
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland - Bitget
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Key facts: Outlook Therapeutics reports $1.2M loss; LYTENAVA launched in Europe - TradingView
OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S - GuruFocus
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
OTLK: Net loss of $23.1M, negative revenue, and liquidity risks amid delayed US approval for LYTENAVA - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
OTLK: European sales of LYTENAVA doubled, but US approval for ONS-5010 remains uncertain - TradingView
Outlook Therapeutics swings to Q1 net loss - TradingView
Outlook Therapeutics Advances LYTENAVA™ Expansion in Europe with Launch Scheduled for Austria and Regulatory Update for ONS-5010 in the U.S. - Quiver Quantitative
Outlook Therapeutics Earnings Report: Q1 Overview - Benzinga
Published on: 2026-02-16 11:51:16 - mfd.ru
Sell Signal: Can Outlook Therapeutics Inc. stock maintain growth trajectoryDay Trade & Free Accurate Trade Setup Notifications - mfd.ru
OTLK Stock Price, Forecast & Analysis | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA - The Globe and Mail
SPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlo - GuruFocus
Key facts: Outlook Therapeutics Seeks FDA Meeting on ONS-5010 Issues - TradingView
IPO Launch: What drives Renasant Corporations stock priceQuarterly Earnings Summary & Daily Growth Stock Tips - baoquankhu1.vn
Outlook Therapeutics submits Type A meeting request to FDA following Complete Response Letter - marketscreener.com
Outlook Therapeutics Submit Type A Meeting Request To FDA Following CRL - Nasdaq
Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter - TradingView
Outlook Therapeutics (OTLK) Faces FDA Request for Additional Evi - GuruFocus
Outlook Therapeutics seeks FDA meeting after response letter - Traders Union
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewswire
Risk Check: Is Outlook Therapeutics Inc a top pick in the sectorEarnings Beat & Technical Confirmation Alerts - baoquankhu1.vn
Decliners Report: Can Outlook Therapeutics Inc reach all time highs this yearTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Recap: Should you buy the dip on Outlook Therapeutics IncAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Outlook Therapeutics Is Suddenly Everywhere – Is This Tiny Eye-Drug Stock a Sleeping Monster or Ju - AD HOC NEWS
Is Outlook Therapeutics Inc stock a buy or sellJuly 2025 Decliners & Intraday High Probability Setup Alerts - baoquankhu1.vn
Can Outlook Therapeutics Inc. reach all time highs this yearJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
Bull Run: Will Outlook Therapeutics Inc outperform the market in YEARWeekly Market Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Profit Recap: Can Manhattan Associates Inc expand into new markets2025 Earnings Impact & Long-Term Investment Growth Plans - baoquankhu1.vn
Outlook Therapeutics (OTLK) price target decreased by 43.42% to 5.48 - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ) - The Globe and Mail
Outlook Therapeutics Faces Another FDA Setback For Lytenava - Finimize
Insider Trends: Is Outlook Therapeutics Inc stock a falling knife or bargain buy2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
US FDA declines to approve Outlook Therapeutics' eye disease drug - AOL.com
Will Outlook Therapeutics Inc. stock outperform international peersJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - ulpravda.ru
How Outlook Therapeutics Inc. (41ON) stock trades pre earnings2025 Price Momentum & Low Drawdown Trading Strategies - ulpravda.ru
How Outlook Therapeutics Inc. stock reacts to bond yieldsEarnings Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):